Piper Sandler Maintains Overweight on Axsome Therapeutics, Lowers Price Target to $238
Piper Sandler analyst David Amsellem maintains Axsome Therapeutics (NASDAQ:AXSM) with a Overweight and lowers the price target from $258 to $238.
Share
Why It Matters
An expert investor watcher still likes Axsome but lowered their price guess. This means the company looks good but maybe not quite as good as before.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.